Retatrutide is Eli Lilly's next-generation obesity drug and, on the data so far, the most powerful weight-loss medicine in late-stage development. This report sets out where it stands, what its arrival means for markets worldwide, and — for teams weighing a move — a structured framework for bringing it (or a competitor) into a new country.
Drug profile at a glance
Retatrutide is a triple-hormone agonist, acting on the GLP-1, GIP, and glucagon receptors — one more target than Lilly's own tirzepatide and two more than Novo Nordisk's semaglutide. That third lever (glucagon) is associated with higher energy expenditure, and is the leading explanation for the unusually deep weight loss seen in trials.
Clinical status (verified)
- Triumph-1: approximately 30% average body-weight reduction at 104 weeks.
- Triumph-2 (type 2 diabetes): about 21% at 80 weeks.
- Triumph-3 (cardiovascular disease): about 23% at the highest doses.
- Regulatory: Eli Lilly has said it plans to file with the U.S. FDA in Q1 2027.
Why it matters
If approved, retatrutide would raise the efficacy ceiling of an obesity market already worth tens of billions of dollars and growing fast. For every player in the value chain — from multinationals to national distributors, payers, and health systems — that reshapes competitive dynamics, pricing pressure, and access planning.
What the full report covers
- Market outlook and demand drivers (with a clearly-labelled estimate model)
- Competitive landscape: semaglutide, tirzepatide, oral GLP-1s, and the next wave
- Global regulatory status and a realistic approval timeline
- The country-launch playbook — an eight-step framework covering IP reality, regulatory pathway, market access & reimbursement, supply chain, and go-to-market
- Key risks and watch-items over the next 24 months